Gene expression profiling in polycythemia vera using cDNA microarray technology.

Polycythemia vera (PV) is a myeloproliferative disorder characterized by an increased proliferation of all three myeloid lineages. The molecular pathogenesis of PV is unknown. Using cDNA microarrays comprising 6000 human genes, we studied the gene expression profile of granulocytes obtained from 11 PV patients compared with granulocytes obtained from healthy individuals. We found that 147 genes were up-regulated by >/==" BORDER="0">2.5 fold in the majority of PV patients. Eleven of these 147 genes were up-regulated in all PV patients studied and may represent a molecular signature for this disorder. An increase in the expression of several protease inhibitors with affinity for proteases that promote apoptosis in neutrophils (e.g., cystatin F, secretory leukocyte protease inhibitor), as well as the up-regulation of a number of antiapoptotic and survival factors was found (e.g., adrenomedullin, p38 mitogen-activated protein kinase). We speculate that the deregulation of these factors may inhibit normal apoptosis and promote cell survival in the granulocytes of patients with PV. These PV-specific expression changes are likely to be biologically important in the pathophysiology of this disorder.

[1]  K. Malcolm,et al.  A Genomic and Proteomic Analysis of Activation of the Human Neutrophil by Lipopolysaccharide and Its Mediation by p38 Mitogen-activated Protein Kinase* , 2002, The Journal of Biological Chemistry.

[2]  M. Asaka,et al.  Autocrine production of epithelial cell-derived neutrophil attractant-78 induced by granulocyte colony-stimulating factor in neutrophils. , 2002, Blood.

[3]  M. Rees,et al.  Adrenomedullin and the microvasculature. , 2002, Trends in pharmacological sciences.

[4]  J. Spivak.  THE OPTIMAL MANAGEMENT OF POLYCYTHAEMIA VERA , 2002, British journal of haematology.

[5]  T. Soussi,et al.  The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. , 2002, Gene.

[6]  T. Andersson,et al.  p38 Mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase activities have opposite effects on human neutrophil apoptosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[8]  E. Estey,et al.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.

[9]  C. Dai,et al.  Increased expression of the INK4a/ARF locus in polycythemia vera. , 2001, Blood.

[10]  M. Lübbert,et al.  Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.

[11]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[12]  S. Nishimura,et al.  Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-beta, overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells. , 1999, Advances in enzyme regulation.

[13]  S. Nishimura,et al.  CMAP: a novel cystatin-like gene involved in liver metastasis. , 1999, Cancer research.

[14]  C. Richard,et al.  Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. , 1998, The New England journal of medicine.

[15]  A. Beaulieu,et al.  Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis. , 1997, The Biochemical journal.

[16]  A. Green,et al.  Pathogenesis of polycythaemia vera , 1996, The Lancet.

[17]  J. Geffner,et al.  Neutrophil apoptosis induced by proteolytic enzymes. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[18]  E. Evans,et al.  Characterization and chromosomal localization of ELANH2, the gene encoding human monocyte/neutrophil elastase inhibitor. , 1995, Genomics.

[19]  A. D’Andrea,et al.  Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. , 1994, Blood.

[20]  F. Birg,et al.  Expression of the ETS2 and transferrin receptor genes in Philadelphia‐positive chronic myeloid leukemia patients with a reciprocal t(3;21) , 1992, Genes, chromosomes & cancer.

[21]  R. Abramson,et al.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Goldberg,et al.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[23]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[24]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[25]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.